Cite
HARVARD Citation
Bennett, J. et al. (2016). Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 388 (10045), pp. 661-672. [Online].